» Articles » PMID: 17196235

Urinary Arsenic Profile Affects the Risk of Urothelial Carcinoma Even at Low Arsenic Exposure

Overview
Specialties Pharmacology
Toxicology
Date 2007 Jan 2
PMID 17196235
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

Arsenic exposure is associated with an increased risk of urothelial carcinoma (UC). To explore the association between individual risk and urinary arsenic profile in subjects without evident exposure, 177 UC cases and 313 age-matched controls were recruited between September 2002 and May 2004 for a case-control study. Urinary arsenic species including the following three categories, inorganic arsenic (As(III)+As(V)), monomethylarsonic acid (MMA(V)) and dimethylarsinic acid (DMA(V)), were determined with high-performance liquid chromatography-linked hydride generator and atomic absorption spectrometry. Arsenic methylation profile was assessed by percentages of various arsenic species in the sum of the three categories measured. The primary methylation index (PMI) was defined as the ratio between MMA(V) and inorganic arsenic. Secondary methylation index (SMI) was determined as the ratio between DMA(V) and MMA(V). Smoking is associated with a significant risk of UC in a dose-dependent manner. After multivariate adjustment, UC cases had a significantly higher sum of all the urinary species measured, higher percent MMA(V), lower percent DMA(V), higher PMI and lower SMI values compared with controls. Smoking interacts with the urinary arsenic profile in modifying the UC risk. Differential carcinogenic effects of the urinary arsenic profile, however, were seen more prominently in non-smokers than in smokers, suggesting that smoking is not the only major environmental source of arsenic contamination since the UC risk differs in non-smokers. Subjects who have an unfavorable urinary arsenic profile have an increased UC risk even at low exposure levels.

Citing Articles

Matrine Suppresses Arsenic-Induced Malignant Transformation of SV-HUC-1 Cells via NOX2.

Wang L, Qiu N, Tong S, Yu Y, Xi S, Wang F Int J Mol Sci. 2024; 25(16).

PMID: 39201564 PMC: 11354282. DOI: 10.3390/ijms25168878.


Low-to-Moderate Arsenic Exposure and Urothelial Tract Cancers with a Long Latent Period of Follow-Up in an Arseniasis Area.

Liao P, Lee C, Wang S, Chiou H, Chen C, Seak C J Epidemiol Glob Health. 2023; 13(4):807-815.

PMID: 37725327 PMC: 10686965. DOI: 10.1007/s44197-023-00152-x.


The Folic Acid and Creatine Trial: Treatment Effects of Supplementation on Arsenic Methylation Indices and Metabolite Concentrations in Blood in a Bangladeshi Population.

Abuawad A, Bozack A, Navas-Acien A, Goldsmith J, Liu X, Hall M Environ Health Perspect. 2023; 131(3):37015.

PMID: 36976258 PMC: 10045040. DOI: 10.1289/EHP11270.


Metabolic Changes and Their Associations with Selected Nutrients Intake in the Group of Workers Exposed to Arsenic.

Sijko M, Janasik B, Wasowicz W, Kozlowska L Metabolites. 2023; 13(1).

PMID: 36676995 PMC: 9866863. DOI: 10.3390/metabo13010070.


Joint effects of genomic markers and urinary methylation capacity associated with inorganic arsenic metabolism on the occurrence of cancers among residents in arseniasis-endemic areas: A cohort subset with average fifteen-year follow-up.

Liao P, Hsu K, Chiou H, Chen C, Lee C Biomed J. 2022; 44(6 Suppl 2):S218-S225.

PMID: 35297370 PMC: 9068568. DOI: 10.1016/j.bj.2020.10.005.